Skip to main content
. 2015 Sep 4;7(6):1094–1103. doi: 10.1080/19420862.2015.1087636

Figure 3.

Figure 3.

Dextrose-mediated aggregation of Avastin in immunodepleted serum. (A) Dextrose-mediated aggregation of Avastin in modified human serum. Lanes 1–3, protein adsorption/aggregation in human plasma. Lanes 4–10, protein aggregation in complete human serum (Ctl) or immunodepleted human serum void of one of the following complement proteins: C1q, C2, C3, C4, factor B (FctB), or factor D (FctD). (B) Dextrose-mediated aggregation of Avastin in human plasma (Pla) or in fresh mouse serum from wild-type (WT) or C3 knocked out (C3KO) mouse.